KUKJE PHARMA Co., Ltd. Statistics
Want to see KR:002720 full AI Analyst Report?
KUKJE PHARMA Co., Ltd. (002720) Stock Statistics & Valuation Metrics
Total Valuation
KUKJE PHARMA Co., Ltd. has a market cap or net worth of KRW 60.68B. The enterprise value is KRW 85.86B.
- Market Cap
- KRW 60.68B
- Enterprise Value
- KRW 85.86B
Share Statistics
KUKJE PHARMA Co., Ltd. has 21,159,832 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 21,159,832
- Owned by Insiders
- ―
- Owned by Institutions
- 0.02%
Financial Efficiency
KUKJE PHARMA Co., Ltd.’s return on equity (ROE) is 0.06 and return on invested capital (ROIC) is 3.45%.
- Return on Equity (ROE)
- 0.06
- Return on Assets (ROA)
- 0.03
- Return on Invested Capital (ROIC)
- 3.45%
- Return on Capital Employed (ROCE)
- 0.05
- Revenue Per Employee
- 645.21M
- Profits Per Employee
- 20.95M
- Employee Count
- 272
- Asset Turnover
- 0.92
- Inventory Turnover
- 3.19
Valuation Ratios
The current PE Ratio of KUKJE PHARMA Co., Ltd. is 17.79. KUKJE PHARMA Co., Ltd.’s PEG ratio is -0.34.
- PE Ratio
- 17.79
- PS Ratio
- 0.34
- PB Ratio
- 0.63
- Price to FCF
- -15.76
- Price to Operating Cash Flow
- 81.29
- PEG Ratio
- -0.34
Income Statement
In the last 12 months, KUKJE PHARMA Co., Ltd. had revenue of 175.50B and earned 5.70B in profits. Earnings per share was 279.51.
- Revenue
- 175.50B
- Gross Profit
- 92.97B
- Operating Income
- 6.18B
- Pretax Income
- 6.44B
- Net Income
- 5.70B
- EBITDA
- 9.41B
- Earnings Per Share (EPS)
- 279.51
Cash Flow
In the last 12 months, operating cash flow was 6.69B and capital expenditures -4.37B, giving a free cash flow of 2.32B billion.
- Operating Cash Flow
- 6.69B
- Free Cash Flow
- 2.32B
- Free Cash Flow per Share
- -189.06
Dividends & Yields
KUKJE PHARMA Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of 1.01%
- Dividend Per Share
- ―
- Dividend Yield
- 1.01%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -6.34%
- Earnings Yield
- 5.62%
Stock Price Statistics
- Beta
- -0.05
- 52-Week Price Change
- -31.73%
- 50-Day Moving Average
- 3492.60
- 200-Day Moving Average
- 3905.08
- Relative Strength Index (RSI)
- 32.62
- Average Volume (3m)
- 1.99M
Important Dates
KUKJE PHARMA Co., Ltd. upcoming earnings date is Mar 25, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 16, 2026
- Next Earnings Date
- Mar 25, 2027
- Ex-Dividend Date
- ―
Financial Position
KUKJE PHARMA Co., Ltd. as a current ratio of 1.09, with Debt / Equity ratio of 31.12%
- Current Ratio
- 1.09
- Quick Ratio
- 0.67
- Debt to Market Cap
- 0.34
- Net Debt to EBITDA
- 2.09
- Interest Coverage Ratio
- 6.81
Taxes
In the past 12 months, KUKJE PHARMA Co., Ltd. has paid 738.54M in taxes.
- Income Tax
- 738.54M
- Effective Tax Rate
- 0.11
Enterprise Valuation
KUKJE PHARMA Co., Ltd. EV to EBITDA ratio is 11.11, with an EV/FCF ratio of -20.37.
- EV to Sales
- 0.44
- EV to EBITDA
- 11.11
- EV to Free Cash Flow
- -20.37
- EV to Operating Cash Flow
- 105.07
Balance Sheet
KUKJE PHARMA Co., Ltd. has KRW 15.72B in cash and marketable securities with KRW 31.39B in debt, giving a net cash position of -KRW 15.67B billion.
- Cash & Marketable Securities
- KRW 15.72B
- Total Debt
- KRW 31.39B
- Net Cash
- -KRW 15.67B
- Net Cash Per Share
- -KRW 740.33
- Tangible Book Value Per Share
- KRW 4,633.42
Margins
Gross margin is 53.14%, with operating margin of 2.11%, and net profit margin of 1.93%.
- Gross Margin
- 53.14%
- Operating Margin
- 2.11%
- Pretax Margin
- 1.96%
- Net Profit Margin
- 1.93%
- EBITDA Margin
- 3.99%
- EBIT Margin
- 2.11%
Analyst Forecast
The average price target for KUKJE PHARMA Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 5.62%
- EPS Growth Forecast
- -52.20%
Scores
- Smart Score
- ―
- AI Score
- 62

